Content area

|
|

Immunterapi mod Alzheimers sygdom

Forfatter(e)
Alexander Christian Falkentoft & Steen Gregers Hasselbalch Nationalt Videnscenter for Demens, Neurologisk Klinik, Neurocentret, Rigshospitalet Ugeskr Læger 2016;178:V07150588
Reference: 
Ugeskr Læger 2016;178:V07150588
Blad nummer: 
Sidetal: 
2-6
Immunotherapy for Alzheimer’s disease
Passive anti-beta-amyloid (Aß) immunotherapy has been shown to clear brain Aß deposits. Results from phase III clinical trials in mild-to-moderate Alzheimer’s disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase 3 trials with solanezumab showed a reduction in cognitive decline in patients with mild AD. Solanezumab and new monoclonal antibodies are being tested in patients with prodromal and preclinical AD in search for a disease-modifying treatment.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Camilla Bang | 29/11
2 kommentarer
af Stine Madsen-Østerbye | 29/11
1 Kommentar
af Kaj Seidelin | 29/11
6 kommentarer
af Pedram Kazemi-Esfarjani | 28/11
2 kommentarer
af Ulf Bern Jensen | 24/11
2 kommentarer
af Bodil Marie Nielsen | 24/11
2 kommentarer
af Toke Seierøe Barfod | 23/11
2 kommentarer
af Thorkild I.A. Sørensen | 20/11
1 Kommentar
af Kim Varming | 20/11
1 Kommentar